EYE AREA CARE 119 Epidermis
Reduced melanin production in 3D eyelid skin model
Reinforced barrier function in 3D eyelid skin model
Lymphatic system Par-1
Reduced lymphatic permeability Vascular system
Reduced vascular permeability
Ligament tissue Restoring ligament tissue resilience and strength
Muscle Restoring the muscle
regenerative capacity and muscle tonicity
Figure 5: In vitro efficacy summary of AI-designed peptide across seven soft tissues 0 days
deeper soft tissues, including adipose, muscle and ligament-support compartments, influence the three-dimensional architecture of the eye contour.1,2,6–10
obtained after the treatment with AI-designed peptide is shown in Figure 5.
Clinical translation: comprehensive eye contour improvement The mechanistic findings were translated into visible benefits in a multicentric, double-blind, placebo-controlled, half-face clinical study involving 118 evaluable volunteers from Spain and China. The panel included both men and women aged 31–73 years, with skin phototypes II–IV and visible eye contour concerns. Volunteers applied a formulation containing
2% of the AI-designed peptide solution on one hemiface and placebo on the other hemiface twice daily for 28 days. Evaluation time points and imaging methods were selected to capture the main visible concerns of the eye contour, including vascular dark circles, eye bags, crow’s feet wrinkles and upper eyelid drooping. After seven days, redness in the infraorbital
area, measured through the a* parameter, decreased by 2.68%, indicating an early improvement in the vascular component of dark circles (Figure 6). In parallel, after 28 days, dark circle pigmentation decreased by 12.24%, while skin lightness increased by 2.94% (data not shown). Eye bags were evaluated by three-dimensional
image analysis. After 28 days, eye bag volume decreased by 8.42% and eye bag area decreased by 6.40% versus baseline (Figure 7). Crow’s feet wrinkle volume decreased by 8.87% after seven days and by 12.26% after 28 days (Figure 8A). Upper eyelid appearance was assessed
using computer vision analysis of eye height as a visible parameter associated with droopy eyelid improvement. After seven days, an increase in eye height was observed, with the selected visual material highlighting a 20.0% difference versus placebo (Figure 8B). These findings are consistent with the in vitro effects observed in muscle models.
www.personalcaremagazine.com A 7 days A summary of the in vitro efficacies C 2% Eyeseryl All-In peptides -8.7%
Placebo -2.9%
B 0 days 28 days
14 12 10 8 6 4 2 0
vs initial time: *p<0.05 vs placebo: *p<0.05
Figure 6: AI-designed peptide improves both vascular and pigmented components of dark circles in a clinical study. (A) Representative eye contour images showing the reduction of infraorbital skin redness at baseline and after seven days of treatment. (B) Representative macrophotographs of the eye contour area at baseline and after 28 days of treatment, illustrating the visible improvement in dark circle appearance. (C) Three-dimensional colour map generated from the average pigmentation data of all volunteers after 28 days of treatment, showing a reduction in periorbital pigmentation compared with baseline
Discussion The data presented here support a different framework for understanding periocular ageing. The AI-designed peptide was initially selected for its ability to modulate PAR-1, an upstream regulator of endothelial permeability and inflammation. Through its involvement in vascular and lymphatic barrier dysfunction and NF-κB-mediated inflammatory signalling, PAR-1 may contribute to the amplification of microenvironmental disruption across multiple periocular tissues. The broad efficacy profile observed across
seven soft tissues suggests that targeting this upstream driver may help interrupt the Amplifying Release Cycle and reduce the downstream consequences associated with visible ageing.
The observed effects on barrier function,
pigmentation, extracellular matrix organization, adipose remodelling, muscle function and ligament-support structures support a broad activity profile across periocular tissues. Together, these findings suggest that a seven-
soft-tissue strategy may provide a more complete scientific rationale for holistic eye contour rejuvenation than traditional single-concern approaches.
Conclusions Eyeseryl All-In peptide represents a new- generation approach to eye contour care, in which artificial intelligence-assisted discovery was used to identify a peptide with activity against a central regulator of the periocular microenvironment.
October 2026 PERSONAL CARE MAGAZINE
Dermis Increased production of collagen and elastic network in 3D eyelid skin model Reduced glycation
Adipose tissue Reduced adipogenesis Enhanced lipolysis
Periorbital pigmentation
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132
